http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오늘 본 자료
김광진(Kwang-Jin Kim),이용진(Yongjin Lee),강경윤(Kyung-Yun Kang),이성태(Sung-Tae Yee),남상집(Sang-Jip Nam),이미경(Mi-Kyung Lee),이미자(Mi-Ja Lee),손영진(Young-Jin Son) 대한약학회 2018 약학회지 Vol.62 No.6
서 론(Introduction) 실험 방법(Experimental Methods) 결 과(Results) 고 찰(Discussion) 결 론(Conclusion)
RANKL에 의한 파골세포의 분화 억제에 대한 isorhamnetin의 효과
이용진(Yongjin Lee),진호림(Holim Jin),신윤아(Yoon-A Shin),이은영(Eun-Young Lee),남상집(Sang-Jip Nam),손영진(Young-Jin Son) 한국생약학회 2023 생약학회지 Vol.54 No.4
The elderly population is increasing worldwide. Osteoporosis, one of the diseases of the elderly, is a disease that occurs due to a decrease in bone density or changes in bone structure and strength. Osteoporosis mainly occurs in postmenopausal women and the elderly. In the treatment of osteoporosis, it is important to prevent bone loss and inhibit the formation of osteoclasts, which are involved in bone resorption. Research is needed to prevent and treat fractures caused by osteoporosis. In this study, we investigated the effect of isorhamnetin on RANKL-induced osteoclast differentiation. Isorhamnetin significantly inhibited osteoclast differentiation by effectively inhibiting transcription and translation of NFATc1, an essential component in the osteoclast differentiation process. Additionally, the mRNA expression of TRAP, DC-STAMP, and CTSK, genes related to osteoclast differentiation, was suppressed. Therefore, isorhamnetin has the potential to be used as a functional food and therapeutic agent for the treatment of osteoporosis.